ADC Therapeutics SA (ADCT)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about ADC Therapeutics SA (ADCT)
Go deeper and ask any question about ADCT
Company Performance
Current Price
as of Sep 13, 2024$3.10
P/E Ratio
N/A
Market Cap
$299.61M
Description
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Metrics
Overview
- HQEpalinges, VD
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerADCT
- Price$3.1+5.44%
Trading Information
- Market Cap$299.61M
- Float80.81%
- Average Daily Volume (1m)336,673
- Average Daily Volume (3m)624,948
- EPS-$2.56
Company
- Revenue$66.75M
- Rev Growth (1yr)-9.71%
- Net Income-$36.54M
- Gross Margin88.20%
- EBITDA Margin-161.99%
- EBITDA-$28.20M
- EV$126.66M
- EV/Revenue1.90
- P/EN/A
- P/S4.44
Documents
SEC Filings
Factset Street Account
Earnings Calls
Factset